(firstQuint)Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD).

 This is a Phase II, multicenter, open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 72 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.

 This study will evaluate the safety, tolerability, and clinical efficacy of NS-065/NCNP-01 at dose levels of up to 80 mg/kg/week administered by weekly IV infusion over an additional treatment period of 72 weeks.

 Patients who complete the Phase II Dose-finding Study NS-065/NCNP-01-201 are eligible to enroll.

.

 Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)@highlight

This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 72 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.

